BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
Authors
Keywords
-
Journal
Scientific Reports
Volume 5, Issue 1, Pages -
Publisher
Springer Nature
Online
2015-08-03
DOI
10.1038/srep12670
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- PARP inhibitors: A new era of targeted therapy
- (2015) Shifalika Tangutoori et al. MATURITAS
- PARP Inhibitors as P-glyoprotein Substrates
- (2014) Denise Lawlor et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699)
- (2014) Selvi Durmus et al. PHARMACEUTICAL RESEARCH
- Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
- (2013) Peter Bouwman et al. CLINICAL CANCER RESEARCH
- IMP3 Protein Promotes Chemoresistance in Breast Cancer Cells by Regulating Breast Cancer Resistance Protein (ABCG2) Expression
- (2013) Sanjoy Samanta et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
- (2013) Emeline Valton et al. Scientific Reports
- Breast cancer, side population cells and ABCG2 expression
- (2012) K.M. Britton et al. CANCER LETTERS
- Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
- (2012) Lenka Oplustilova et al. CELL CYCLE
- Targeted therapy for triple-negative breast cancer: Where are we?
- (2012) Michael J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Treatment of triple negative breast cancer (TNBC): current options and future perspectives
- (2010) M. De Laurentiis et al. CANCER TREATMENT REVIEWS
- Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists
- (2010) Sunil Badve et al. MODERN PATHOLOGY
- Susceptibility Pathways in Fanconi's Anemia and Breast Cancer
- (2010) Alan D. D'Andrea NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications
- (2009) Yvette Drew et al. DRUG RESISTANCE UPDATES
- Triple negative breast cancers: Clinical and prognostic implications
- (2009) S.J. Dawson et al. EUROPEAN JOURNAL OF CANCER
- Triple-negative breast cancer: Novel therapies and new directions
- (2009) Sumanta Kumar Pal et al. MATURITAS
- DNA Damage, Aging, and Cancer
- (2009) Jan H.J. Hoeijmakers NEW ENGLAND JOURNAL OF MEDICINE
- Targeted therapy for cancer using PARP inhibitors
- (2008) Christopher J Lord et al. CURRENT OPINION IN PHARMACOLOGY
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now